111’s (YI) Sell (E+) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 111 (NASDAQ:YI) in a research report released on Wednesday morning,Weiss Ratings reports.

111 Stock Up 2.0 %

Shares of NASDAQ:YI opened at $8.36 on Wednesday. The company has a market capitalization of $71.48 million, a P/E ratio of -2.09 and a beta of 0.41. 111 has a 52-week low of $4.14 and a 52-week high of $15.80. The stock’s fifty day simple moving average is $6.40 and its 200-day simple moving average is $7.40.

111 (NASDAQ:YI) last released its earnings results on Wednesday, November 27th. The company reported ($0.20) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On 111

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock valued at $191,000 after acquiring an additional 305,339 shares during the period. Napean Trading & Investment Co Singapore PTE Ltd purchased a new position in shares of 111 in the 4th quarter worth about $245,000. Finally, FIL Ltd purchased a new stake in shares of 111 during the 4th quarter worth about $450,000. 21.32% of the stock is currently owned by hedge funds and other institutional investors.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.